Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Rabkin, US
Ariel Rabkin, Berkeley, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080229096 | Network identity management system and method - Users of Internet services (e.g., SKYPE messaging service, GOOGLETALK messaging service, AOL INSTANT MESSENGER messaging service, and MICROSOFT MESSENGER messaging service) that are initially identified using separate identifiers that may be associated with respective service providers (e.g., email addresses) can manage network identities using a single unified set of account information managed by a registry service. The registry authenticates the user's request(s) to bind a service provider identity to his or her personal registry user record. The registry internally associates the service provider identity to an internal unique identifier that is not exposed to subscribers. When a second user wishes to communicate with a first user, the second user provides any service provider identity that is believed to be associated with the first user to determine if the specified service provider identity appears to match the intended subscriber. If so, the second user may specify a nickname (unique to the second subscriber but not necessarily globally unique) to be associated internally within the registry with the internal unique identifier of the first subscriber as part of the second subscriber's user record. Later, even if the first subscriber has relinquished the service provider identity that was originally used to find the first subscriber, the second subscriber can still find the first subscriber by using the associate nickname without either subscriber ever knowing the internal unique identifier of the first subscriber. | 09-18-2008 |
Dmitry J. Rabkin, Framingham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080208319 | Multi-Segment Modular Stent And Methods For Manufacturing Stents - A modular stent comprises at least one stent module including an intermediate segment consisting of one of either a closed-cell segment or a Z-segment and a pair of end segments connected to respective longitudinal ends of said intermediate segment, each end segment consisting of the other of said closed-cell segment or Z-segment, each closed-cell segment consisting solely of at least one annular closed-cell ring and each Z-segment consisting solely of at least one annular Z-ring. A method of manufacturing a stent form a small diameter tube includes laser-cutting the small diameter tube to define a plurality of longitudinally adjacent Z-rings, providing interconnector portions of said tube integrally joining facing aligned or offset Z-rings, expanding the small diameter tube, and removing predetermined interconnector portions from the expanded tube to provide the predetermined desired arrangement of interconnected closed-cell rings and Z-rings. | 08-28-2008 |
| 20100087913 | Temporary, Repositionable Or Retrievable Intraluminal Devices - A stent formed of a metallic material having a two-way memory adapted to be retrieved or repositioned after delivery includes an elongated tubular body and at least one crown connected to a respective longitudinal end of said body, the crown including a plurality of unconnected leaves, each leaf having a longitudinally extending frame connected at one end to said end of said body. A method of manufacturing the stent to that the crown has a greater two-way memory effect than the body is disclosed. | 04-08-2010 |
| 20100174358 | Multi-Segment Modular Stent And Methods For Manufacturing Stents - A modular stent comprises at least one stent module including an intermediate segment consisting of one of either a closed-cell segment or a Z-segment and a pair of end segments connected to respective longitudinal ends of said intermediate segment, each end segment consisting of the other of said closed-cell segment or Z-segment, each closed-cell segment consisting solely of at least one annular closed-cell ring and each Z-segment consisting solely of at least one annular Z-ring. A method of manufacturing a stent form a small diameter tube includes laser-cutting the small diameter tube to define a plurality of longitudinally adjacent Z-rings, providing interconnector portions of said tube integrally joining facing aligned or offset Z-rings, expanding the small diameter tube, and removing predetermined interconnector portions from the expanded tube to provide the predetermined desired arrangement of interconnected closed-cell rings and Z-rings. | 07-08-2010 |
Peter Rabkin, Cupertino, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100078758 | MIIM DIODES - A metal-insulator diode is disclosed. In one aspect, the metal-insulator diode comprises a first electrode comprising a first metal, a first region comprising a first insulating material, a second region comprising a second insulating material, and a second electrode comprising a second metal. The first region and the second region reside between the first electrode and the second electrode. The second insulating material is doped with nitrogen. Note that the second insulating material may have an interface with either the first electrode or the second electrode. | 04-01-2010 |
| 20100078759 | MIIM DIODES HAVING STACKED STRUCTURE - A metal-insulator diode is disclosed. In one aspect, the metal-insulator diode comprises first and second electrode and first and second insulators arraigned as follows. An insulating region has a trench formed therein. The trench has a bottom and side walls. The first electrode, which comprises a first metal, is on the side walls and over the bottom of the trench. A first insulator has a first interface with the first electrode. At least a portion of the first insulator is within the trench. A second insulator has a second interface with the first insulator. At least a portion of the second insulator is within the trench. The second electrode, which comprises a second metal, is in contact with the second insulator. The second electrode at least partially fills the trench. | 04-01-2010 |
Samuel Rabkin, Swampscott, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090285860 | Cancer immunotherapy - Method of stimulating an immune response (e.g., to treat cancer) include administering to a subject a composition including dendritic cells incubated with (i) oHSV-infected tumor cells or a composition derived therefrom, or (ii) tumor cells plus oHSV, as well as methods of preparing such compositions, are described. | 11-19-2009 |
Samuel D. Rabkin, Lynn, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110070262 | Viral Vectors and Their Use in Therapeutic Methods - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 03-24-2011 |
Samuel D. Rabkin, Chevy Chase, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090053178 | USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator. | 02-26-2009 |